Bevacizumab maintenance in metastatic colorectal cancer: How long? - Wikidata - awgldk - TriplyDB

Bevacizumab maintenance in metastatic colorectal cancer: How long?

Bevacizumab maintenance in metastatic colorectal cancer: How long?

http://www.wikidata.org/entity/Q41837018

about

Bevacizumab maintenance in metastatic colorectal cancer: How long?

http://www.wikidata.org/entity/Q41837018

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Bevacizumab maintenance in metastatic colorectal cancer: How long?

@en

type

label

Bevacizumab maintenance in metastatic colorectal cancer: How long?

@en

prefLabel

Bevacizumab maintenance in metastatic colorectal cancer: How long?

@en

P1433

Q41837018-F8885764-98CA-421B-8EAA-3A00FED7EBF6

P1476

Q41837018-451DFA17-3D67-4ABE-9D8C-2583E954878F

P2093

Q41837018-163D7C0F-C209-4017-A6A4-63C252C71164

Q41837018-4FC8328E-92E0-43E4-9C77-D1DE66370078

Q41837018-7999C6CD-7CB5-4D08-8036-F51988FC2D78

Q41837018-9D735CEC-402B-499F-9448-56B2273632ED

Q41837018-BCD94F26-8AE3-4F0D-8195-15A51F620E6C

Q41837018-C22A1BFD-8C03-402D-99CE-48B533C235DC

Q41837018-C7959B71-A11D-489B-8ED0-0B95E242F75F

Q41837018-CFE29794-62EF-4C1B-8450-5881BCE9A296

P2860

Q41837018-14BFA989-A377-4D7B-A69D-5539AF27AB83

Q41837018-1C5EA19D-C672-4FD5-94AB-BD8560B7E649

Q41837018-29A3EEDE-1123-49A3-A3FD-F699459C3BB1

Q41837018-910C83E2-238D-48BC-BAF6-92A430745C0F

Q41837018-99B4F667-4D04-4A26-963A-E2AB80D2A75F

Q41837018-9D4D9A27-9F8C-43DA-8257-DA97734E3509

Q41837018-A1D6B9D8-ABFC-4CBF-BC8C-458CB54FAC7C

Q41837018-AE884BDA-5187-49B9-8D1C-8BB756E82C76

Q41837018-B5F95503-2251-4314-A17D-AA6B9082EADA

Q41837018-C77799EB-3EDE-417A-86B5-ED9A50DB78F7

P304

Q41837018-EFCAD2DC-58CC-484D-84A3-6998AB7EF033

P31

Q41837018-3384EF6A-A428-4159-85B8-8FB31DDF05A3

Q41837018-7519f303-c9cf-4978-a75f-5ffd3b78b280

P356

Q41837018-C1E2AF2A-6DFE-4A42-B718-8EE9098B6445

P433

Q41837018-3DDC2BE6-71C2-4FB2-93B0-2E847CB23DCE

P478

Q41837018-FA33B325-EB63-4DCF-ADEF-291A7C92A614

P50

Q41837018-258AED48-E8DE-4900-AE3F-B97BB52A88EF

Q41837018-266282D2-CDEF-4DC5-8B58-70CD76AE16D8

P577

Q41837018-7B5932D3-0789-4797-9C92-43FC8ADC47F5

P5875

Q41837018-8AD4D0D7-C886-4B73-A492-E5CB268D2937

P698

Q41837018-50D75B0A-12A2-4A3C-8374-E9EF81ABF62B

P921

Q41837018-4BBB9566-ACF0-49F9-B3FB-BEE530CB09C4

P932

Q41837018-9EF93861-7451-444F-AE7A-F4D770CFA336

P356

WJCC.V2.I11.717

P1433

World journal of clinical cases

P1476

Bevacizumab maintenance in metastatic colorectal cancer: How long?

@en

P2093

Chiara Alessandra Cella

http://www.w3.org/2001/XMLSchema#string

Chiara Carlomagno

http://www.w3.org/2001/XMLSchema#string

Francesca Di Pietro

http://www.w3.org/2001/XMLSchema#string

Giovanni Fiore

http://www.w3.org/2001/XMLSchema#string

Lucia Raimondo

http://www.w3.org/2001/XMLSchema#string

Roberto Moretto

http://www.w3.org/2001/XMLSchema#string

Sabino De Placido

http://www.w3.org/2001/XMLSchema#string

Stefano Pepe

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Cancer statistics, 2013

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

Metastatic colorectal cancer: from improved survival to potential cure.

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

P304

717-723

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12998/WJCC.V2.I11.717

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Alfonso De Stefano

Francesco Jacopo Romano

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268788625

http://www.w3.org/2001/XMLSchema#string

P698

25405197

http://www.w3.org/2001/XMLSchema#string

P921

P932

4233413

http://www.w3.org/2001/XMLSchema#string